This video is featured in the 2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Insights: CCTG BR.31 - Adjuvant Durvalumab in Completely Resected NSCLC

18 views
October 21, 2024
Comments 0
Login to view comments. Click here to Login